ClearNote Health’s Avantect® Pancreatic Cancer Test Approved in New York ClearNote Health has received approval from the New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP) for its Avantect® Pancreatic Cancer Test. This approval allows New York clinicians…
Arcus Biosciences Retains Casdatifan Rights and Announces $150M Stock Offering Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage global biopharmaceutical company specializing in cancer treatments, announced today that Gilead’s exclusive option rights to its potential best-in-class HIF-2α inhibitor, casdatifan, have expired. In…
Allurion to Combine GLP-1 Therapy with Balloon for Obesity Treatment Allurion Technologies, Inc. (NYSE: ALUR), a company focused on combating obesity, has announced plans to launch a clinical study exploring the combination of the Allurion Balloon with GLP-1 agonists. The…
Oneview Healthcare Launches ‘Ovie’ Care Assistant to Ease Nursing Burden Oneview Healthcare has launched Ovie, a groundbreaking GenAI product designed to offer personalized, real-time support for patients and their families during hospital stays. Oneview Healthcare has launched Ovie, a transformative…
WELIREG® (belzutifan) Gains First European Commission Approval for Two Indications Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α)…
XRHealth Acquires RealizedCare, Expanding to Largest AI-Driven Therapeutic XR Platform XRHealth, a leader in therapeutic virtual reality (VR), mixed reality (MR), and extended reality (XR) solutions, has acquired the immersive digital therapeutics company RealizedCare. This acquisition enhances XRHealth’s AI-powered, value-based…
GeneDx Reports Q4 and 2024 Financial Results, Provides 2025 Guidance GeneDx Holdings Corp. (Nasdaq: WGS), a leader in genomic testing for improved health outcomes, reported its financial results for the fourth quarter and full year of 2024. The company highlighted…
Galderma’s Nemluvio® (Nemolizumab) Approved for Atopic Dermatitis and Prurigo Nodularis in the UK and Switzerland Galderma has announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Swissmedic have granted marketing authorization for Nemolizumab, a monoclonal antibody…
CancerX Unveils 2025 Accelerator to Propel Oncology Innovation CancerX, a public-private partnership aimed at accelerating cancer innovation, has announced the launch of its 2025 Accelerator cohort. This year’s group includes a remarkable selection of digital health and artificial intelligence startups…
ICC Tribunal Rules in Favor of AOP Health in BESREMi® Arbitration Case An International Chamber of Commerce (ICC) tribunal has issued a partial final award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in an ongoing legal dispute with…